Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 18/20 | 0.82 |
| ▸ | OPRM1 | P35372 | 17/20 | 0.82 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.76 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3407329 | 0.91 | OPRM1 (1.00) | OPRL1OPRM1OPRK1 | |
| SCHEMBL1119612 | 0.87 | OPRL1 (1.00) | OPRL1OPRM1OPRK1 | |
| SCHEMBL1119663 | 0.85 | OPRM1 (0.67) | OPRL1OPRM1OPRK1OPRD1ALDH1A1 | |
| SCHEMBL28299186 | 0.82 | OPRM1 (0.58) | OPRL1OPRM1OPRK1OPRD1MEN1 | |
| SCHEMBL3409091 | 0.79 | OPRM1 (1.00) | OPRL1OPRM1OPRK1 | |
| SCHEMBL27805494 | 0.78 | OPRL1 (0.64) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL3410725 | 0.77 | OPRM1 (1.00) | OPRL1OPRM1OPRK1 | |
| SCHEMBL3410738 | 0.77 | OPRM1 (1.00) | OPRL1OPRM1OPRK1 | |
| SCHEMBL3413521 | 0.76 | OPRL1 (1.00) | OPRL1OPRM1OPRK1 | |
| SCHEMBL5212823 | 0.75 | OPRM1 (0.53) | OPRL1OPRM1OPRK1OPRD1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2280941-B1 | (HETERO-)ARYL CYCLOHEXANE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2015-05-06 | — | — | EP | disclosed |
| US-7977370-B2 | (Hetero)aryl cyclohexane derivatives | GRUENENTHAL GMBH (DE) | 2011-07-12 | — | — | US | disclosed |
| EP-2280941-A1 | (HETERO-)ARYL CYCLOHEXANE DERIVATIVES | Grünenthal GmbH (DE) | 2011-02-09 | — | — | EP | disclosed |
| WO-2009118163-A1 | (HETERO-)ARYL CYCLOHEXANE DERIVATIVES | Grünenthal GmbH (DE) | 2009-10-01 | — | — | WO | disclosed |
| US-20090247573-A1 | (HETERO)ARYL CYCLOHEXANE DERIVATIVES | GRUNENTHAL GMBH (DE) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247573-A1 | (HETERO)ARYL CYCLOHEXANE DERIVATIVES | OPRL1, OPRM1, OPRD1 | OPRL1 1/4885OPRM1 2/4885OPRK1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.